Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 19/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.69 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504649 | 1.00 | MAP2K2 (0.69) | MAP2K2MAP2K1USP30 | |
| SCHEMBL4565081 | 1.00 | MAP2K2 (0.69) | MAP2K2MAP2K1USP30 | |
| SCHEMBL4503125 | 0.96 | MAP2K2 (0.69) | MAP2K2MAP2K1USP30 | |
| SCHEMBL4503128 | 0.96 | MAP2K2 (0.69) | MAP2K2MAP2K1USP30 | |
| SCHEMBL4515142 | 0.96 | MAP2K2 (0.69) | MAP2K2MAP2K1USP30 | |
| SCHEMBL4520777 | 0.95 | MAP2K2 (0.70) | MAP2K2MAP2K1 | |
| SCHEMBL4507167 | 0.89 | MAP2K2 (0.62) | MAP2K2MAP2K1 | |
| SCHEMBL4503771 | 0.89 | MAP2K2 (0.62) | MAP2K2MAP2K1 | |
| SCHEMBL4503773 | 0.89 | MAP2K2 (0.62) | MAP2K2MAP2K1 | |
| SCHEMBL4511773 | 0.86 | MAP2K2 (0.71) | MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | MAP2K2 9/4885MAP2K1 12/4885USP30 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.